7 November 2019 - EIP Pharma today announced that the Division of Neurology Products of the U.S. FDA has granted fast track designation to neflamapimod for investigation as a treatment of dementia with Lewy bodies.
Separately, EIP Pharma today announced the clinical trial results from the REVERSE-SD study of neflamapimod in early-stage Alzheimer's disease.
A Phase 2 double-blind, placebo-controlled, 16-week treatment proof-of-concept study ("AscenD-LB") of neflamapimod in mild-to-moderate DLB called is currently enrolling patients.